全文获取类型
收费全文 | 10489篇 |
免费 | 636篇 |
国内免费 | 15篇 |
专业分类
耳鼻咽喉 | 52篇 |
儿科学 | 363篇 |
妇产科学 | 269篇 |
基础医学 | 1229篇 |
口腔科学 | 76篇 |
临床医学 | 1762篇 |
内科学 | 1806篇 |
皮肤病学 | 106篇 |
神经病学 | 1106篇 |
特种医学 | 212篇 |
外科学 | 833篇 |
综合类 | 108篇 |
一般理论 | 126篇 |
预防医学 | 1506篇 |
眼科学 | 155篇 |
药学 | 753篇 |
中国医学 | 7篇 |
肿瘤学 | 671篇 |
出版年
2023年 | 42篇 |
2022年 | 95篇 |
2021年 | 198篇 |
2020年 | 103篇 |
2019年 | 202篇 |
2018年 | 208篇 |
2017年 | 177篇 |
2016年 | 190篇 |
2015年 | 230篇 |
2014年 | 334篇 |
2013年 | 524篇 |
2012年 | 729篇 |
2011年 | 760篇 |
2010年 | 418篇 |
2009年 | 389篇 |
2008年 | 699篇 |
2007年 | 660篇 |
2006年 | 686篇 |
2005年 | 682篇 |
2004年 | 670篇 |
2003年 | 646篇 |
2002年 | 550篇 |
2001年 | 116篇 |
2000年 | 111篇 |
1999年 | 136篇 |
1998年 | 119篇 |
1997年 | 91篇 |
1996年 | 102篇 |
1995年 | 97篇 |
1994年 | 67篇 |
1993年 | 71篇 |
1992年 | 78篇 |
1991年 | 85篇 |
1990年 | 72篇 |
1989年 | 84篇 |
1988年 | 76篇 |
1987年 | 56篇 |
1986年 | 61篇 |
1985年 | 72篇 |
1984年 | 49篇 |
1983年 | 35篇 |
1982年 | 49篇 |
1981年 | 38篇 |
1980年 | 37篇 |
1979年 | 30篇 |
1978年 | 27篇 |
1977年 | 26篇 |
1976年 | 23篇 |
1975年 | 23篇 |
1974年 | 19篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
131.
Zarazuela Zolkipli Cheryl Longman Sue Brown Nazneen Rahman S. E. Holder Francesco Muntoni 《European journal of paediatric neurology》2003,7(6):401-406
Infantile Systemic Hyalinosis is a rare autosomal recessive entity, characterised by deposition of hyaline material in skin and bone, often complicated by visceral involvement. The characteristic features are marked delay in motor milestones attributed to severe progressive flexion contractures of proximal and distal joints, and skin and mucosal hypertrophy and thickening, followed by failure to thrive. Pain secondary to osteolytic lesions is also a predominant feature. We report a patient with Infantile Systemic Hyalinosis, confirmed by the clinical findings, who also displayed clear evidence of proximal muscle weakness. Muscle biopsy revealed myopathic changes, which have not been reported previously. We suggest that skeletal muscle is involved in Infantile Systemic Hyalinosis and contributes to the characteristic poor outcome of these patients. 相似文献
132.
133.
Factors associated with breast cancer clinical trials participation and enrollment at a large academic medical center. 总被引:5,自引:0,他引:5
Michael S Simon Wei Du Lawrence Flaherty Philip A Philip Patricia Lorusso Cheryl Miree Daryn Smith Diane R Brown 《Journal of clinical oncology》2004,22(11):2046-2052
PURPOSE: The practice patterns of medical oncologists at a large National Cancer Institute Comprehensive Cancer Center in Detroit, MI were evaluated to better understand factors associated with accrual to breast cancer clinical trials. PATIENTS AND METHODS: From 1996 to 1997, physicians completed surveys on 319 of 344 newly evaluated female breast cancer patients. The 19-item survey included clinical data, whether patients were offered clinical trial (CT) participation and enrollment, and when applicable, reasons why they were not. Multivariate analyses using logistic regression were performed to evaluate predictors of an offer and enrollment. RESULTS: The patients were 57% white, 32% black, and 11% other/unknown race. One hundred six (33%) were offered participation and 36 (34%) were enrolled. In multivariate analysis, CTs were less likely offered to older women (mean age, 52 years for those offered v 57 years for those not offered; P =.0005) and black women (21% of blacks offered v 42% of whites; P =.0009). Women with stage 1 disease, poor performance status, and those who were previously diagnosed were also less likely to be offered trials. None of these factors were significant predictors of enrollment. Women were not offered trials because of ineligibility (57%), lack of available trials (41%), and noncompliance (2%). Reasons for failed enrollment included patient refusal (88%) and failed eligibility (12%). CONCLUSION: It is important for cooperative groups to design studies that will accommodate a broader spectrum of patients. Further work is needed to assess ways to improve communication about breast cancer CT participation to all eligible women. 相似文献
134.
Wen Qing Yang Xueqing Lun Cheryl Ann Palmer M Elizabeth Wilcox Huong Muzik Zhong Qiao Shi Richard Dyck Matt Coffey Brad Thompson Mark Hamilton Sandra G Nishikawa Penny M A Brasher Kevin Fonseca David George N Berry Rewcastle Randal N Johnston Doug Stewart Patrick W K Lee Donna L Senger Peter A Forsyth 《Clinical cancer research》2004,10(24):8561-8576
PURPOSE: Human reovirus type 3 has been proposed to kill cancer cells with an activated Ras signaling pathway. The purpose of this study was to investigate the efficacy of reovirus in immunocompetent glioma animal models and safety/toxicity in immunocompetent animals, including nonhuman primates. EXPERIMENTAL DESIGN: Racine glioma cells 9L and RG2 were implanted s.c. or intracranially in Fisher 344 rats with or without reovirus antibodies, followed by treatment of reovirus. To study whether reovirus kills contralateral tumors in the brain and to determine viral distribution, we established an in situ dual tumor model followed by reovirus intratumoral inoculation only into the ipsilateral tumor. To evaluate neurotoxicity/safety of reovirus, Cynomolgus monkeys and immunocompetent rats were given intracranially with reovirus, and pathological examination and/or behavioral studies were done. Viral shedding and clinical biochemistry were systematically studied in monkeys. RESULTS: Intratumorally given reovirus significantly suppressed the growth of both s.c. and intracranially tumors and significantly prolonged survival. The presence of reovirus-neutralizing antibodies did not abort the reovirus' antitumor effect. Reovirus inhibited glioma growth intracranially in the ipsilateral but not the contralateral tumors; viral load in ipsilateral tumors was 15 to 330-fold higher than the contralateral tumors. No encephalitis or behavioral abnormalities were found in monkeys and rats given reovirus intracranially. No treatment-related clinical biochemistry changes or diffuse histopathological abnormality were found in monkeys inoculated intracranially with Good Manufacturing Practice prepared reovirus. Microscopic changes were confined to the region of viral inoculation and were dose related, suggesting reovirus intracranially was well tolerated in nonhuman primates. CONCLUSIONS: These data show the efficacy and safety of reovirus when it is used in the treatment of gliomas in immunocompetent hosts. Inoculation of reovirus into the brain of nonhuman primates did not produce significant toxicities. 相似文献
135.
Ranjana Advani George A Fisher Bert L Lum Charro Jambalos Cheryl D Cho Marvin Cohen Ashwin Gollerkeri Branimir I Sikic 《Clinical cancer research》2003,9(14):5187-5194
PURPOSE: The purpose of this study was to establish the maximum tolerated dose (MTD), dose-limiting toxicities (DLTs), and preliminary activity of BMS-188797 administered weekly. EXPERIMENTAL DESIGN: Patients with advanced malignancies were treated with escalating doses of BMS-188797 on a weekly schedule as a 1-h i.v. infusion. Plasma sampling was performed to characterize the pharmacokinetics of BMS-188797. RESULTS: Eighteen patients with advanced malignancies were enrolled at three dose levels ranging from 35 to 65 mg/m(2). The number of patients evaluated at each dose level was as follows: 35 mg/m(2) (n = 3); 50 mg/m(2) (n = 9); and 65 mg/m(2) (n = 6). At 65 mg/m(2), three of six patients had a DLT (one had grade 4 neutropenia lasting >7 days, and two had grade 3 diarrhea). Expansion of the 50-mg/m(2) dose cohort to nine patients established this dose as the MTD, with one patient experiencing a DLT (grade 4 neutropenia with fever). Two partial responses were observed (lung cancer, 7+ months; ovarian cancer, 6+ months durations), as well as two minor responses (esophageal cancer, 5 months; ovarian cancer, 5 months). Both patients with partial responses had been clinically resistant to paclitaxel. Plasma pharmacokinetic mean values of maximum concentration (C(max)) and area under the curve (AUC(0-48)) increased in a dose-dependent manner within the range of doses used in this study, and in three of four patients, the DLTs correlated with AUC. CONCLUSIONS: The MTD and the recommended Phase II dose of weekly BMS-188797 is 50 mg/m(2). The drug demonstrates antitumor activity in taxane-refractory solid tumors and is now being evaluated in combination with carboplatin. 相似文献
136.
137.
Int6 expression can predict survival in early-stage non-small cell lung cancer patients. 总被引:1,自引:0,他引:1
138.
Phase II study of gefitinib, fluorouracil, leucovorin, and oxaliplatin therapy in previously treated patients with metastatic colorectal cancer. 总被引:7,自引:0,他引:7
Timothy Kuo Cheryl D Cho Joanne Halsey Heather A Wakelee Ranjana H Advani James M Ford George A Fisher Branimir I Sikic 《Journal of clinical oncology》2005,23(24):5613-5619
PURPOSE: To investigate the gefitinib, fluorouracil (FU), leucovorin, and oxaliplatin regimen (IFOX) in previously treated patients with metastatic colorectal cancer. PATIENTS AND METHODS: Eligible patients had stage IV colorectal adenocarcinoma and had demonstrated progression or intolerance to a prior chemotherapy regimen not including oxaliplatin. Each cycle consisted of 14 days. Cycle 1 consisted of oxaliplatin 85 mg/m2 intravenously (IV) during 2 hours on day 1, hours 0 to 2; leucovorin 200 mg/m2 IV on days 1 and 2, hours 0 to 2; FU 400 mg/m2 IV push on days 1 and 2; and FU 600 mg/m2 IV on days 1 and 2, hours 2 to 24 (FOLFOX-4). All subsequent cycles consisted of FOLFOX-4 with gefitinib at 500 mg/d administered orally throughout the 14-day cycle. RESULTS: Twenty-seven patients were enrolled onto the study. The median number of prior chemotherapy regimens was two, and 74% of all patients received prior irinotecan. Nine of the 27 patients (33%) and six of the 20 patients (30%) who had prior FU and irinotecan had a partial response by Response Evaluation Criteria in Solid Tumors Group criteria. Median overall survival was 12.0 months. Median event-free survival was 5.4 months. Grade 3 to 4 toxicities included neutropenia (48%), diarrhea (48%), nausea (22%), and vomiting (15%). CONCLUSION: IFOX is an active regimen in patients with previously treated metastatic colorectal adenocarcinoma, demonstrating higher response rates than those reported with FOLFOX-4 alone in a similar patient population. 相似文献
139.
Feasibility and acceptability of a motivational interviewing breastfeeding peer support intervention
Lauren Copeland Laura Merrett Cheryl McQuire Aimee Grant Nina Gobat Sally Tedstone Rebecca Playle Sue Channon Julia Sanders Rhiannon Phillips Billie Hunter Amy Brown Deborah Fitzsimmons Michael Robling Shantini Paranjothy 《Maternal & child nutrition》2019,15(2)
An uncontrolled study with process evaluation was conducted in three U.K. community maternity sites to establish the feasibility and acceptability of delivering a novel breastfeeding peer‐support intervention informed by motivational interviewing (MI; Mam‐Kind). Peer‐supporters were trained to deliver the Mam‐Kind intervention that provided intensive one‐to‐one peer‐support, including (a) antenatal contact, (b) face‐to‐face contact within 48 hr of birth, (c) proactive (peer‐supporter led) alternate day contact for 2 weeks after birth, and (d) mother‐led contact for a further 6 weeks. Peer‐supporters completed structured diaries and audio‐recorded face‐to‐face sessions with mothers. Semistructured interviews were conducted with a purposive sample of mothers, health professionals, and all peer‐supporters. Interview data were analysed thematically to assess intervention acceptability. Audio‐recorded peer‐support sessions were assessed for intervention fidelity and the use of MI techniques, using the MITI 4.2 tool. Eight peer‐supporters delivered the Mam‐Kind intervention to 70 mothers in three National Health Service maternity services. Qualitative interviews with mothers (n = 28), peer‐supporters (n = 8), and health professionals (n = 12) indicated that the intervention was acceptable, and health professionals felt it could be integrated with existing services. There was high fidelity to intervention content; 93% of intervention objectives were met during sessions. However, peer‐supporters reported difficulties in adapting from an expert‐by‐experience role to a collaborative role. We have established the feasibility and acceptability of providing breastfeeding peer‐support using a MI‐informed approach. Refinement of the intervention is needed to further develop peer‐supporters' skills in providing mother‐centred support. The refined intervention should be tested for effectiveness in a randomised controlled trial. 相似文献
140.
Guido Marcucci Wendy Stock Guowei Dai Rebecca B Klisovic Shujun Liu Marko I Klisovic William Blum Cheryl Kefauver Dorie A Sher Margaret Green Mollie Moran Kati Maharry Steven Novick Clara D Bloomfield James A Zwiebel Richard A Larson Michael R Grever Kenneth K Chan John C Byrd 《Journal of clinical oncology》2005,23(15):3404-3411